title: Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
abstract: OBJECTIVE
  An ideal vaccine therapy for tumors should activate both effector and memory immune responses against tumor-specific antigens. Here we investigated the effect of CpG oligodeoxynucleotides (CpG-ODN) for their ability to potentiate the activity of tumor antigen-pulsed bone marrow-derived dendritic cells (DC) in a vaccine model for the treatment of murine renal cell carcinoma (RENCA).
  
  
  METHODS
  First we evaluated the effects of a murine renal cell carcinoma (RENCA) on immune cell activity in a mouse model using in vitro assays for T-cell proliferation and natural killer cell activation. To overcome the immune suppression of the tumor, we s.c. injected groups of 10 mice with dendritic cells and tumor cells. We compared the effect of different conditioning regimens of the DCs with RENCA antigen and/or CpG-ODNs before injection by measuring tumor size twice a week.
  
  
  RESULTS
  Tumor growth was shown to negatively affect spleen cell and T-cell proliferation, IFN-gamma production, natural killer cell activity, and NF-kappaB activation in T cells. In this model, we have shown that RENCA-pulsed CpG-ODN-treated DCs were able not only to significantly reduce tumor growth but also to prevent tumor implantation in 60% of mice. Tumor-free mice were resistant to tumor challenge and the immunity conferred by the vaccine was transferable and tumor specific.
  
  
  CONCLUSIONS
  This data show that RENCA down-modulates the immune response, and DC vaccine therapy, in conjunction with CpG-ODN, can restore tumor-specific immunity.
authors.affiliation: Department of Surgery (Urology), McGill University, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4, Canada.
authors.forename: Fanny
authors.initials: F
authors.lastname: Chagnon
authors.forename: Simon
authors.initials: S
authors.lastname: Tanguay
authors.forename: Ozdem Levent
authors.initials: OL
authors.lastname: Ozdal
authors.forename: Meng
authors.initials: M
authors.lastname: Guan
authors.forename: Zeynep Z
authors.initials: ZZ
authors.lastname: Ozen
authors.forename: Jean-Sébastien
authors.initials: JS
authors.lastname: Ripeau
authors.forename: Mario
authors.initials: M
authors.lastname: Chevrette
authors.forename: Mostafa M
authors.initials: MM
authors.lastname: Elhilali
authors.forename: Lu Ann
authors.initials: LA
authors.lastname: Thompson-Snipes
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use; D000704:Analysis of Variance; D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology / Q000276:immunology; D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D045744:Cell Line, Tumor; D018899:CpG Islands / Q000235:genetics; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology*; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007680:Kidney Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D009838:Oligodeoxyribonucleotides / Q000276:immunology / Q000494:pharmacology* / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D009838:Oligodeoxyribonucleotides